Wolff Schmiegel - Concepedia

Author

Wolff Schmiegel

Also Known As

E. Montanya, I. Koop, Olaf Ortmann, Peter Bronsert, S. Seeber, Schmiegel, W, Schmiegel, Wolff, V Steinke-Lange, W H Schmiegel, W SCHMIEGEL

1.2K

Publications

25.7K

Citations

H-Index

156

Concepts

All Affiliations

Ruhr University Bochum Universitätsklinikum Knappschaftskrankenhaus Bochum BG University Hospital Bergmannsheil Bochum Heidelberg University German Cancer Research Center

About

Wolff Schmiegel is an author at Ruhr University Bochum specializing in medicine, pathology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	48	102	11.1K
2	Health Sciences	13	13	568
3	Public Health	6	6	717
4	Engineering	3	3	114
5	Natural Sciences	1	1	20

Wolff Schmiegel

199

Publications

22.2K

Citations

H-Index

Page 1

	Year	Citations
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk, The Lancet Surgical OncologyEsophageal CancerGastrointestinal OncologyMedicineVersus Fluorouracil	2019	2.4K
Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study Eric Van Cutsem, Chris Twelves, Jim Cassidy, Journal of Clinical Oncology	2001	1K
Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans Michael A. Nauck, Ulrich Niedereichholz, Rainer Ettler, American Journal of Physiology-Endocrinology and Metabolism	1997	812
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, Claudia Pauligk, The Lancet Oncology Surgical OncologyEsophageal CancerGastrointestinal OncologyMedicineSurgical Pathology	2016	713
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Mieke Schutte, Ralph H. Hruban, Joseph Geradts, PubMed Tumor BiologyPancreatic CancerMedicineP16 GeneCancer Cell Biology	1997	665
Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma G. Riethmüller, Rudolf Gruber, E. Schneider-Gädicke, The Lancet Surgical OncologyGastrointestinal OncologyMedicineImmunologyColorectal Cancer	1994	638
Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database Mev Dominguez–Valentin, Julian R. Sampson, Toni T. Seppälä, Genetics in Medicine	2019	615
Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers Michael A. Nauck, Markus M. Heimesaat, Kai Behle, The Journal of Clinical Endocrinology & Metabolism	2002	574
Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. G. Riethmüller, E Holz, Günter Schlimok, Journal of Clinical Oncology	1998	516
Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12 Emmanouil Fokas, Michael Allgäuer, Bülent Polat, Journal of Clinical Oncology	2019	505

Page 1